Clinical Trial Update: Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer [Phase 1]

View source ↗

Summary

A Phase 1 bioequivalence study of DWZ2501 in patients with advanced BRCA-mutated high-grade ovarian cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• DWZ2501

Snippet

Sponsor: Daewoong Pharmaceutical Co. LTD. | Conditions: Cancer, Ovarian Cancer | Phase 1 | Status: RECRUITING